|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Akira S, Nishio Y, Inoue M, Wang XJ, Wei
S, Matsusaka T, Yoshida K, Sudo T, Naruto M and Kishimoto T:
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3
p91-related transcription factor involved in the gp130-mediated
signaling pathway. Cell. 77:63–71. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhong B, Liu Q and Liu Y, Xiong X and Liu
Y: Expressions of STAT3, p-STAT3 and E-cadherin in colorectal
cancer and clinical implications. Zhonghua Wei Chang Wai Ke Za Zhi.
17:594–597. 2014.(In Chinese). PubMed/NCBI
|
|
4
|
Bromberg J and Wang TC: Inflammation and
cancer: IL-6 and STAT3 complete the link. Cancer Cell. 15:79–80.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang C, Yang G, Jiang T, Huang K, Cao J
and Qiu Z: Effects of IL-6 and AG490 on regulation of Stat3
signaling pathway and invasion of human pancreatic cancer cells in
vitro. J Exp Clin Cancer Res. 29:512010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adam N, Rabe B, Suthaus J, Grötzinger J,
Rose-John S and Scheller J: Unraveling viral interleukin-6 binding
to gp130 and activation of STAT-signaling pathways independently of
the interleukin-6 receptor. J Virol. 83:5117–5126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Wang Y, Han C, Li P and Zhang H:
Colorectal cancer progression is associated with accumulation of
Th17 lymphocytes in tumor tissues and increased serum levels of
interleukin-6. Tohoku J Exp Med. 233:175–182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aneknan P, Kukongviriyapan V, Prawan A,
Kongpetch S, Sripa B and Senggunprai L: Luteolin arrests cell
cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in
human cholangiocarcinoma cells. Asian Pac J Cancer Prev.
15:5071–5076. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zushi S, Shinomura Y, Kiyohara T, Miyazaki
Y, Kondo S, Sugimachi M, Higashimoto Y, Kanayama S and Matsuzawa Y:
STAT3 mediates the survival signal in oncogenic ras-transfected
intestinal epithelial cells. Int J Cancer. 78:326–330. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Masuda M, Suzui M, Yasumatu R, Nakashima
T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB:
Constitutive activation of signal transducers and activators of
transcription 3 correlates with cyclin D1 overexpression and may
provide a novel prognostic marker in head and neck squamous cell
carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI
|
|
12
|
Van Cutsem E and Nordlinger B: Advanced
colorectal cancer: ESMO Clinical Practice Guidelines for treatment.
Ann Oncol. 21(Suppl 5): v93–v97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meng QX, Roubin RH and Hanrahan JR:
Ethnopharmacological and bioactivity guided investigation of five
TCM anticancer herbs. J Ethnopharmacol. 148:229–238. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niu Y and Meng QX: Chemical and
preclinical studies on Hedyotis diffusa with anticancer potential.
J Asian Nat Prod Res. 15:550–565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yeh YC, Chen HY, Yang SH, Lin YH, Chiu JH,
Lin YH and Chen JL: Hedyotis diffusa combined with Scutellaria
barbata are the core treatment of Chinese herbal medicine used for
breast cancer patients: a population-based study. Evid Based
Complement Alternat Med. 2014:2023782014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin J, Wei L, Shen A, Cai Q, Xu W, Li H,
Zhan Y, Hong Z and Peng J: Hedyotis diffusa Willd extract
suppresses Sonic hedgehog signaling leading to the inhibition of
colorectal cancer angiogenesis. Int J Oncol. 42:651–656. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin M, Lin J, Wei L, Xu W, Hong Z, Cai Q,
Peng J and Zhu D: Hedyotis diffusa Willd extract inhibits HT-29
cell proliferation via cell cycle arrest. Exp Ther Med. 4:307–310.
2012.PubMed/NCBI
|
|
18
|
Lin J, Wei L, Xu W, Hong Z, Liu X and Peng
J: Effect of Hedyotis diffusa Willd extract on tumor angiogenesis.
Mol Med Rep. 4:1283–1288. 2011.PubMed/NCBI
|
|
19
|
Cai Q, Lin J, Wei L, Zhang L, Wang L, Zhan
Y, Zeng J, Xu W, Shen A, Hong Z and Peng J: Hedyotis diffusa Willd
inhibits colorectal cancer growth in vivo via inhibition of STAT3
signaling pathway. Int J Mol Sci. 13:6117–6128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin J, Chen Y, Wei L, Chen X, Xu W, Hong
Z, Sferra TJ and Peng J: Hedyotis diffusa Willd extract induces
apoptosis via activation of the mitochondrion-dependent pathway in
human colon carcinoma cells. Int J Oncol. 37:1331–1338.
2010.PubMed/NCBI
|
|
21
|
Fiandalo MV and Kyprianou N: Caspase
control: protagonists of cancer cell apoptosis. Exp Oncol.
34:165–175. 2012.PubMed/NCBI
|
|
22
|
Lin J, Chen Y, Wei L, Shen A, Sferra TJ,
Hong Z and Peng J: Ursolic acid promotes colorectal cancer cell
apoptosis and inhibits cell proliferation via modulation of
multiple signaling pathways. Int J Oncol. 43:1235–1243.
2013.PubMed/NCBI
|
|
23
|
Wang S, Wu X, Tan M, Gong J, Tan W, Bian
B, Chen M and Wang Y: Fighting fire with fire: poisonous Chinese
herbal medicine for cancer therapy. J Ethnopharmacol. 140:33–45.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qi F, Li A, Inagaki Y, et al: Chinese
herbal medicines as adjuvant treatment during chemo- or
radio-therapy for cancer. Biosci Trends. 4:297–307. 2010.
|
|
25
|
Cheng HM, Li CC, Chen CY, Lo HY, Cheng WY,
Lee CH, Yang SZ, Wu SL, Hsiang CY and Ho TY: Application of
bioactivity database of Chinese herbal medicine on the therapeutic
prediction, drug development, and safety evaluation. J
Ethnopharmacol. 132:429–437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang SW and Sun YM: The IL-6/JAK/STAT3
pathway: potential therapeutic strategies in treating colorectal
cancer (Review). Int J Oncol. 44:1032–1040. 2014.PubMed/NCBI
|
|
27
|
He Z, Ke J, He X, Lian L, Sun L, Chen Z,
Wu X and Lan P: Inflammation promotes the development of
colitis-associated colorectal cancer. Zhonghua Wei Chang Wai Ke Za
Zhi. 17:706–710. 2014.(In Chinese). PubMed/NCBI
|
|
28
|
Dai Y, Jiao H, Teng G, Wang W, Zhang R,
Wang Y, Hebbard L, George J and Qiao L: Embelin reduces
colitis-associated tumorigenesis through limiting IL-6/STAT3
signaling. Mol Cancer Ther. 13:1206–1216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang Q, Bournazou E, Sansone P, Berishaj
M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al:
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and
metastasis. Neoplasia. 15:848–862. 2013.PubMed/NCBI
|
|
30
|
Zhao Y, Yao J, Wu XP, Zhao L, Zhou YX,
Zhang Y, You QD, Guo QL and Lu N: Wogonin suppresses human alveolar
adenocarcinoma cell A549 migration in inflammatory microenvironment
by modulating the IL-6/STAT3 signaling pathway. Mol Carcinog. Jun
29–2014.(Epub ahead of print). View
Article : Google Scholar
|
|
31
|
Landskron G, De la Fuente M, Thuwajit P,
Thuwajit C and Hermoso MA: Chronic inflammation of cytokines in the
tumor microenvironment. J Immunol Res. 2014:1491852014. View Article : Google Scholar
|
|
32
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal
transducer and activator of transcription-3, inflammation, and
cancer: how intimate is the relationship? Ann NY Acad Sci.
1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
